Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334194 | 1.00 | CNR1 (0.44) | CNR1DAGLAPRKCANAAALMNA | |
| SCHEMBL19387572 | 1.00 | CNR1 (0.44) | CNR1DAGLAPRKCANAAALMNA | |
| SCHEMBL23870660 | 1.00 | CNR1 (0.44) | CNR1DAGLAPRKCANAAALMNA | |
| SCHEMBL31295625 | 0.93 | LMNA (0.45) | CNR1DAGLAPRKCALMNACES2 | |
| SCHEMBL9473711 | 0.90 | GAA (0.39) | CNR1DAGLALMNA | |
| SCHEMBL9473779 | 0.86 | HSD17B10 (0.42) | CNR1DAGLALMNA | |
| SCHEMBL14071589 | 0.84 | CNR1 (0.36) | CNR1DAGLANAAALMNA | |
| Pidolic Acid SCHEMBL27784562 | 0.83 | CNR1 (0.46) | CNR1DAGLANAAALMNA | |
| Pidolic Acid SCHEMBL27784564 | 0.83 | CNR1 (0.46) | CNR1DAGLANAAALMNA | |
| Dodecanoate SCHEMBL6028403 | 0.83 | GPR84 (0.50) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CNR1 2111/4885DAGLA 3674/4885PRKCA 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.